SynthesisBMC infectious diseases2025
Genotypic diversity of multi- and extensively drug-resistant Mycobacterium tuberculosis in Iran: a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMonitoring the genetic diversity of the drug-resistant Mycobacterium tuberculosis (Mtb) population contributes to gaining better insight into the bacterial dynamics and informing effective strategies to tackle the challenge of drug resistance. This meta-analysis study investigates the pooled prevalence of Mtb genotypes among Iranian multidrug-resistant (MDR)/extensively drug-resistant (XDR)-TB patients.
methodsWe performed a systematic search across repositories, including PubMed, Scopus, Web of Science, and Iranian databases, to find studies reporting Mtb genotype prevalence among Iranian MDR/XDR-TB patients through 31 August 2024. Random-effects or fixed-effect models were used to evaluate the pooled proportion. Statistical analysis was conducted using a meta package in R software.
resultsIn this meta-analysis, 26 out of 34 included studies focused on MDR genotypes, while the remaining studies addressed the prevalence of pre-/XDR genotypes. The prevalence results for MDR genotypes showed that Haarlem (28.5%, 95% CI: 24.6–32.8), Beijing (25.6%, 95% CI: 22.5–28.9), and URAL (23.8%, 95% CI: 13.3–38.9) were the most predominant genotypes. Genotypes with the lowest proportion included MANU, T, and Uganda ( < 8%). The highest prevalence of pre-/XDR genotypes was identified for Beijing (57.6%, 95% CI: 35.8–76.8) and Haarlem (30.2%, 95% CI: 9.8–63.3), respectively.
conclusionsBased on our findings, Haarlem and Beijing were highlighted as the dominant circulating genotypes among Iranian MDR- and pre-/XDR-TB cases, respectively. As the relationship between these genotypes and high levels of treatment failure has been documented, local tracking dynamics of drug-resistant Mtb population structure are critical to improving our ability to manage local MDR/XDR-TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.